Abstracts tagged "osteoarthritis and pain"

Abstract Number: 456 • 2018 ACR/ARHP Annual Meeting
Effect of Local and Systemic CCR2 Blockade on Knee Hyperalgesia in a Mouse Model of Osteoarthritis
Shingo Ishihara¹, Rachel E. Miller², Richard J. Miller³ and Anne-Marie Malfait⁴, ¹Internal Medicine, Rush University Medical Center, Chicago, IL, ²Biochemistry, Rush University Medical Center, Chicago, IL, ³Pharmacology/Medical Humanities and Bioethics, Northwestern University, Chicago, IL, ⁴Biochemistry & Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Surgical destabilization of the medial meniscus (DMM) in the mouse knee results in slowly progressive osteoarthritis (OA), characterized by moderate joint damage by week…
Abstract Number: 457 • 2018 ACR/ARHP Annual Meeting
Neuropathic Pain in Patients with Knee Osteoarthritis (Preliminary Report)
Pinar Borman¹, Ferda Kaygisiz² and Aysegul Yaman³, ¹Department of Physical Medicine and Rehabilitation, University of Hacettepe Faculty of Medicine, Ankara, Turkey, ²Dept of PMR, Ankara Training and Research Hospital, Ankara, Turkey, ³Dept of PMR, University of Hacettepe Faculty of Medicine, Ankara, Turkey
Background/Purpose: There are limited studies in the literature indicating that neuropathic pain occurs in knee osteoarthritis (OA) (1). The aim of this cross sectional study…
Abstract Number: 954 • 2018 ACR/ARHP Annual Meeting
A New Way to Think about Composite Magnetic Resonance Imaging Scores to Measure Osteoarthritis Severity and Progression
Lori Lyn Price^1,2, Jeffrey B. Driban³, Grace H. Lo⁴, Ming Zhang⁵, Michael P. LaValley⁶ and Timothy E. McAlindon⁷, ¹Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, ²Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, ³Medicine, Division of Rheumatology, Tufts Medical Center, Boston, MA, ⁴Michael E. DeBakey Veterans Affairs Medical Center / Baylor College of Medicine, Houston, TX, ⁵Tufts Medical Center, Boston, MA, ⁶Biostatistics, Boston University School of Public Health, Boston, MA, ⁷Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: For some rheumatologic diseases (e.g. lupus), separate scores evaluate cumulative damage and disease activity. No such strategy exists for osteoarthritis (OA). The prevailing approach…
Abstract Number: 1167 • 2018 ACR/ARHP Annual Meeting
The Role of Fear-Avoidance Model on Pain and Disability in Knee Osteoarthritis Patients
Leticia Leon^1,2, Marta Redondo², Sara Lopez de Felipe², Daniel Garriguez³, Lydia A Alcazar⁴ and Luis Rodriguez-Rodriguez⁵, ¹Rheumatology Department, Hospital Clínical San Carlos, and IdISSC, Madrid, Spain, ²Health Sciences, Universidad Camilo Jose Cela, Madrid, Spain, ³Orthopedics Unit, Hospital Clinico San Carlos, Madrid, Spain, ⁴Rheumatology Department and Heath Research Institute (IdISSC), Hospital Clinico San Carlos, Madrid, Spain, ⁵Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: The model of Fear-Avoidance of pain (anxiety, catastrophization and hypervigilance) appears when the pain has maladaptive interpretations, being associated with greater pain and limitations…
Abstract Number: 1169 • 2018 ACR/ARHP Annual Meeting
Association between Depressive Symptom Subtypes and Disease Severity in Knee Osteoarthritis
Alan Rathbun¹, Megan Schuler², Elizabeth Stuart³, Michelle Shardell⁴, Michelle S. Yau⁵, Joseph Gallo⁶ and Marc C. Hochberg⁷, ¹Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, ²Rand Coportation, Boston, MA, ³Mental Health, Biostatistics, and Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴Translational Gerontology Branch, National Institute on Aging, Baltimore, MD, ⁵Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, MA, ⁶Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁷University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Latent and modifiable factors, such as depressive symptoms, may affect the course of knee OA. Depression is clinically heterogeneous, and effects on pain and…
Abstract Number: 1170 • 2018 ACR/ARHP Annual Meeting
Sex-Specific Associations between Systemic Inflammatory Cytokines and Osteoarthritis Knee Pain
Anthony V. Perruccio¹, J. Denise Power¹, Mayilee Canizares¹, Elizabeth M. Badley^1,2, Mohit Kapoor¹, Rajiv Gandhi¹ and Y. Raja Rampersaud¹, ¹Arthritis Program, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
Background/Purpose: Significant challenges remain in mitigating OA pain and despite growing evidence of sex differences, including in pain and in response to NSAIDs, sex has…
Abstract Number: 2236 • 2017 ACR/ARHP Annual Meeting
Neuropathic Pain in End-Stage Hip and Knee Osteoarthritis: Differences between Men and Women and Differential Associations with Pain at Rest and Pain on Activity
J. Denise Power¹, Anthony V. Perruccio¹, Rajiv Gandhi¹, Christian Veillette¹, J. Roderick Davey¹, Khalid Syed¹, Nizar Mahomed¹ and Y. Raja Rampersaud², ¹Arthritis Program, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Arthritis Program, Krembil Research Institute, University Health Network, Torotno, ON, Canada
Background/Purpose: There is increasing support in the literature for a neuropathic component to OA pain. Our primary objective was to determine whether pain at rest…
Abstract Number: 2852 • 2017 ACR/ARHP Annual Meeting
Widespread Pain Prior to Total Knee Replacement (TKR) Is Associated with Increased Risk of No Clinical Improvement in Pain Among Women
Ernest Vina¹, Di Ran², Erin L. Ashbeck² and C. Kent Kwoh³, ¹Rheumatology, University of Arizona, Tucson, AZ, ²The University of Arizona Arthritis Center, Tucson, AZ, ³University of Arizona, Tucson, AZ
Background/Purpose: Up to 47% of individuals may not have clinically significant improvement following joint replacement surgery. Evidence also suggests that women are less likely to…
Abstract Number: 62 • 2017 ACR/ARHP Annual Meeting
Convergence of Joint Repair and Pain Pathways Via Nerve Growth Factor and p75 Expressing Mesenchymal Stem Cells in Established Osteoarthritis
Thomas Baboolal¹, Sumaiya Al Hinai², Elena Jones², Jill Reckless³, Martyn Foster⁴, Rachel Doyle⁵, Kerry af Forselles⁴, Simon Westbrook⁴ and Dennis McGonagle², ¹PhD, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Rxcelerate Ltd, Cambridge, United Kingdom, ⁴Levicept Ltd, Ramsgate, United Kingdom, ⁵Tetrad Discovery Ltd, Ramsgate, United Kingdom
Background/Purpose: Nerve growth factor (NGF) is a key regulator of pain and anti-NGF therapy reduces osteoarthritis (OA) associated pain. However, anti-NGF therapy is associated with…
Abstract Number: 1193 • 2017 ACR/ARHP Annual Meeting
A Randomized, Placebo-Controlled, Double-Blind, Phase II Clinical Trial of the First-in-Class Imidazoline-2 Receptor Ligand CR4056 in Pain from Knee Osteoarthritis and Disease Phenotypes
Lucio C. Rovati¹, Nadia Brambilla¹, Tomasz Blicharski², Nicholas J Probert³, Cristina Vitalini¹, Giampaolo Giacovelli¹, Federica Girolami¹ and Massimo D'Amato¹, ¹Clinical Research Department, Rottapharm Biotech, Monza, Italy, ²Lubelskie Centrum Diagnostyczne, Świdnik, Poland, ³MAC Clinical Research, Manchester, United Kingdom
Background/Purpose: CR4056 is a novel imidazoline-2 receptor (I2R) ligand endowed with potent analgesic activities in several and diverse animal models of nociceptive and neuropathic pain,…
Abstract Number: 1195 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Subcutaneous Tanezumab in Patients with Knee or Hip Osteoarthritis (NCT01089725)
Charles A. Birbara¹, Eugene J. Dabezies², Aimee M. Burr³, Robert J. Fountaine⁴, Michael D. Smith³, Mark T. Brown³, Christine R. West³, Rosalinda H. Arends³ and Kenneth M. Verburg³, ¹University of Massachusetts Medical School, Worcester, MA, ²Pensacola Research Consultants, Pensacola, FL, ³Pfizer, Inc., Groton, CT, ⁴Pfizer, Inc., Grotoon, CT
Background/Purpose : Tanezumab (TNZ) is a monoclonal antibody that inhibits nerve growth factor and reduces hip or knee osteoarthritis (OA) pain. A placebo-controlled phase 3…
Abstract Number: 2183 • 2017 ACR/ARHP Annual Meeting
Two-Year Changes in Knee Osteoarthritis Symptoms: Comparing Clinical Relevance of Patient-Reported Outcomes By Anchoring to Knee Replacement
C. Kent Kwoh¹, Hans Guehring², Erin Ashbeck³, Michael J Hannon⁴ and Aida Aydemir⁵, ¹University of Arizona Arthritis Center, Tuscan, AZ, ²Merck KGaA, Darmstadt, Germany, ³The University of Arizona Arthritis Center, Tucson, AZ, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA
Background/Purpose: Randomized controlled trials (RCTs) of interventions for knee OA (KOA) may include a patient-reported outcome (PRO) measure as a primary endpoint. Several measures of…
Abstract Number: 2186 • 2017 ACR/ARHP Annual Meeting
The Role of Hip Injury in Pain Exacerbation in Hip Osteoarthritis: an Internet-Based Case-Crossover Study
Kai Fu¹, Joanna Makovey², Ben Metcalf³, Kim Bennell³, Yuqing Zhang⁴, Rebecca Asher⁵, Sarah Meneses², Leticia Deveza² and David Hunter², ¹Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Syndey, Australia, ²Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ³Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, University of Melbourne, Melbourne, Australia, ⁴School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia
Background/Purpose: Pain is the main symptom in hip osteoarthritis (OA) and many patients experience recurrent pain exacerbations. The purpose of this study is to evaluate…
Abstract Number: 2204 • 2017 ACR/ARHP Annual Meeting
Neuropathic Pain in Patients with Knee Osteoarthritis and Related Factors: A Multicenter Longitudinal Study-Preliminary Report
Ece Kaptanoglu¹, Ozlem Şahin², Tiraje Tuncer³, Sami Hizmetli¹, Lale Altan⁴, Figen Ayhan⁵, Ajda Bal⁶, Meral Bilgilisoy⁷, Gulnur Bozbas⁸, Lale Cerrahoglu⁹, Remzi Cevik¹⁰, Tuncay Duruoz¹¹, Deniz Dulgeroglu⁶, Gulcan Gurer¹², Savas Gursoy¹³, Simin Hepguler¹⁴, Cahit Kacar¹⁵, Taciser Kaya¹⁶, Meltem Melikoglu¹⁷, Kemal Nas¹⁸, Suheda Ozcakir¹⁹, Senay Ozdolap²⁰, merih Saridogan²¹, Selda Sarikaya²⁰, Dilsad Sindel²², Omer F Şendur⁸, Canan Tikiz²³ and Hatice Ugurlu²⁴, ¹Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Cumhuriyet University School of Medicine, Sivas, Turkey, ²Department of Physical Medicine and Rehabilitation, Cumhuriyet University School of Medicine, Sivas, Turkey, ³Department of Physical Medicine and Rehabilitation, Akdeniz University School of Medicine, Antalya, Turkey, ⁴Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Uludag University School of Medicine, Bursa, Turkey, ⁵Department of Physical Medicine and Rehabilitation, University of Health Ankara Training and Research Hospital, Ankara, Turkey, ⁶Department of Physical Medicine and Rehabilitation, University of Health Sciences Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey, ⁷Department of Physical Medicine and Rehabilitation, University of Health Sciences Antalya Training and Research Hospital, Antalya, Turkey, ⁸Department of Physical Medicine and Rehabilitation, Adnan Menderes University School of Medicine, Aydin, Turkey, ⁹Department of Physical Medicine and Rehabilitation, Celal Bayar University School of Medicine, Manisa, Turkey, ¹⁰Department of Physical Medicine and Rehabilitation, Dicle University School of Medicine, Diyarbakir, Turkey, ¹¹Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ¹²Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Adnan Menderes University School of Medicine, Aydin, Turkey, ¹³Department of Physical Medicine and Rehabilitation, Gaziantep University School of Medicine, Gaziantep, Turkey, ¹⁴Department of Physical Medicine and Rehabilitation, Ege University School of Medicine, Izmir, Turkey, ¹⁵Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Akdeniz University School of Medicine, Antalya, Turkey, ¹⁶Department of Physical Medicine and Rehabilitation, University of Health Sciences İzmir Bozyaka Training and Research Hospital, Izmir, Turkey, ¹⁷Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Ataturk University School of Medicine, Erzurum, Turkey, ¹⁸Department of Physical Medicine and Rehabilitation, Sakarya University School of Medicine, Sakarya, Turkey, ¹⁹Department of Physical Medicine and Rehabilitation, Uludag University School of Medicine, Bursa, Turkey, ²⁰Department of Physical Medicine and Rehabilitation, Bulent Ecevit University School of Medicine, Zonguldak, Turkey, ²¹Department of Physical Medicine and Rehabilitation, Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey, ²²Department of Physical Medicine and Rehabilitation, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ²³Celal Bayar University School of Medicine, Manisa, Turkey, ²⁴Department of Physical Medicine and Rehabilitation, Necmettin Erbakan University Meram School of Medicine, Konya, Turkey
Background/Purpose: Neuropathic pain (NP) was accused for increased pain and reduced functional capacity in knee osteoarthritis (KO). Here we aimed to find out the prevalence…
Abstract Number: 2232 • 2017 ACR/ARHP Annual Meeting
A Role for CCR2 in Chronic Behavioral and Neuroimmune Changes in the DMM Model of Osteoarthritis
Phuong Tran¹, Shingo Ishihara², Rachel E. Miller³, Richard J. Miller⁴ and Anne-Marie Malfait¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Internal Medicine, Rush University Medical Center, Chicago, IL, ³Biochemistry, Rush University Medical Center, Chicago, IL, ⁴Pharmacology/Medical Humanities and Bioethics, Northwestern University, Chicago, IL
Background/Purpose: The aim of this study was to explore pain-related behaviors and associated cellular changes in the pain pathway in experimental osteoarthritis (OA) induced by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.